Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of November 2019. The report, filed on December 6, 2019, serves to distribute press releases dated November 6, 2019, and November 13, 2019, to U.S. investors.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to attach press releases and does not contain a financial statement or quantitative performance data.
Material Changes
The filing does not disclose material financial changes versus prior periods. It references two press releases (Exhibits 99.1 and 99.2) which likely contain operational updates, but the content of those releases is not included in the provided text.
Guidance, Outlook, and Risks
No guidance, outlook, management commentary, or specific risk factors are detailed in the provided text. The document strictly lists the exhibits and the signature of the Chief Financial Officer, Laure-Hélène Mercier.
Investor Verification Checklist
- Review the full text of the press releases dated November 6, 2019, and November 13, 2019, to understand the specific corporate events triggering this filing.
- Verify the company's latest audited financial statements in the most recent Form 20-F for actual revenue and cash flow data.
- Confirm the status of the company's clinical trials or product development, as these are typical subjects of press releases for biopharmaceutical firms.